Investment Q&A

Q: Peter, it looks like skies are clear for this stock, but I'd be interested in your opinion. Raymond James forecasts a one year double on this stock "on the back of positive news concerning the TULSA- PRO [prostate cancer treatment which provides non-chemo, non-radiation ablation of affected tissue], starting with the technology’s US FDA clearance last August and then announcing its first US sales a few weeks later, moving the company from a clinical development company to a commercial-stage company."

Also, the company recently paid off all remaining debt with CIBC.

So... what do you see as potential hurdles for this one.

Q: In your Feb 7 response to Jerry on PRN after referring to recent strong momentum you say “markets obviously think there is potential here, but the company now needs to start delivering on that potential.”

I would argue that PRN started delivering on the potential long ago – the company received FDA approval Aug 2019 after a successful clinical trial; PRN successfully listed on NASDAQ last fall; the company announced in early January this year a deal and partnership with RadNet, the largest network of outpatient imaging centres in the US; and recently PRN raised US$ 40 million in an equity financing and retired all bank debt ahead of schedule. PRN is now well positioned to scale the business without further dilution.

I recognize there remains commercialization risk and there is reimbursement risk and revenues are essentially non-existent at this early stage but what we have here is a very experienced very competent management team that has done it before with NOVADAQ. Significantly, the CEO Arun and his team are not doing this because they need to money. They will not rush it they will do it right. I think you have mentioned in the past that this is one of the best small cap situations to invest in – assuming you can deal with the volatility and risk.

Q: Lots of activity, have you become more bullish,, certainly seems positive. Would you double down yet? Appreciate your comments.

Q: With all the hype recently what is your evaluation of this company. Ive heard nothing but great news lately. Thanks Dennis Tiplady

Q: Nice move today on what looks like a great start in getting their technology out. You say????

Q: Wow,, what a jump in share value,, do I hold or sell my 7500 shares?

Q: i am curious if you like profound.
they seem to have something that could be huge.
i am in my seventies and everybody around me has prostate problems.dave

Q: On August 16, 2019 Profound Medical was granted US FDA approval for TULSA-PRO. There will be more trials next year for reimbursement but PRN now has regulatory FDA approval in the US and will start commercial sales in Q4 this year. The next week or so will be very interesting.

Q: What is your current view of Profound Medical? They have received clearance from the FDA to market Tulsa-Pro. Is this not huge news? Are there further FDA approvals pending? Although up a few cents (at time of question) it is still not back to July 2018 level of $1. Would you hold?

Q: Hi 5i Team,
Pls comment on Profound Medical earning and outlook. Any positive sign ahead of this company?
Thank you for your kind assistance as always.

Q: comments,please,on recent drop in share value.

Q: Hello,

With the news this morning that Profound Medical's clinical trial proved 96% effective for the prostate cancer patients involved in the study, do you see this as a buy? Or is it still considerably risky, given that FDA approval could take some time or be denied?

Thank you.

Brad

Q: With the new agreement with Glencore how do you feel about the future of NIF.UN? What has to happen to restart the dividend?
I would appreciate your thoughts on PRN also.
Thank you,
Bob

Q: Hi Peter and Ryan,

I am holding Profound Medical , down 35%, but I can find any reasons account for this drop lately, If I am correct they have 32m cash and almost debt free. I do not know what am I missing.

Do you see any fundamental concerns, it is now around 1% of weighting.

Should I continue to hold or sell at loss and move on?

Thank you for your help as always.

Q: Now things start to get really interesting.

Still risk with (i) final clinical trial data in early 2019 and FDA approval contingent on that data; and (ii) commercialization risk assuming FDA approval.

Q: There was a news release today on Profound Medical Corp. Obviously it looks positive, but how significant is it for the company? What timeframe before significant growth should I expect if I start a position in this company. Thanks!

Q: In response to Dennis' question on Profound Medical, when you say you "consider it one of the more interesting small caps in the space currently." Do you mean the medical device space or small caps stocks generally?

Q: This company looks like it could be a winner. What are your views on this one. Your comments please.

Q: Who was the buyer and seller on the big block at the end of the day?

Q: Read an article on this, target price $3.50, Your analysis on this stock please. Is it worth taking a risk?